Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03356457 · ClinicalTrials.gov registry record · Early Phase 1
Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
NCT03356457 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 21 participants.
The verdict
NCT03356457, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
To determine the effect of re-activation of brain glucose metabolism induced by dichloroacetate (DCA) on cognitive function and counterregulatory hormone responses in patients with type 1 diabetes (T1DM) with recurrent hypoglycemia.
Interventions
- DRUG Placebo oral capsule
- DRUG Dichloroacetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-11-30 |
| Est. Completion | 2019-03-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03356457
The ClinicalTrials.gov registry entry for NCT03356457 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03356457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03356457 about?
NCT03356457 is a clinical study titled "Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes". To determine the effect of re-activation of brain glucose metabolism induced by dichloroacetate (DCA) on cognitive function and counterregulatory hormone responses in patients with type 1 diabetes (T1DM) with recurrent hypoglycemia.
What is the current status of trial NCT03356457?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2017-11-30. Estimated completion is 2019-03-20.
What interventions are being tested in trial NCT03356457?
The interventions under investigation include: Placebo oral capsule (DRUG), Dichloroacetate (DRUG).
Who is sponsoring clinical trial NCT03356457?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.